New Federal Policy for Human Research Subjects Delayed

Both higher education and industry associations were advocating for a later implementation date for the Common Rule, which governs human studies.

Written byDiana Kwon
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, BOJAN89

Last week, the US Department of Health and Human Services and 15 government agencies issued a six-month delay to proposed changes to the Common Rule—a federal policy regulating the use of human research subjects—that were set to go live last Friday (January 19). This delay, the agencies write in a statement, would provide additional time for “interested stakeholders” to provide feedback and for research institutions to prepare for the proposed changes. The new effective date for the changes is July 19.

The proposed revisions include stricter rules for informed consent, such as requirements to post brief, comprehensive study summaries at the tops of consent forms and to obtain permission to use stored, unlabeled biospecimens leftover after clinical use. They also include changes to the institutional ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other publications, including Scientific American, Knowable, and Quanta. Diana was a former intern at The Scientist and she holds a master’s degree in neuroscience from McGill University. She’s currently based in Berlin, Germany.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies